Does Blue Cross Blue Shield of Illinois Cover Jardiance?

How BCBSIL Formulary Placement Works for Jardiance

Blue Cross Blue Shield of Illinois organizes prescription drugs into tiered formularies, and Jardiance typically sits on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on your specific plan. Tier placement directly determines your copay or coinsurance rate. Plans purchased through the Illinois Health Insurance Marketplace, employer-sponsored group plans, and individual BCBSIL policies each maintain slightly different formulary lists.

BCBSIL updates its formulary at least annually, and mid-year changes can shift a drug's tier or add new prior authorization requirements. The 2024 American Diabetes Association (ADA) Standards of Care recommend SGLT2 inhibitors like empagliflozin as second-line therapy for patients with type 2 diabetes who have established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease 1. This strong guideline endorsement has pushed most major insurers, BCBSIL included, to maintain formulary access rather than exclude the drug class entirely.

To confirm your plan's current tier placement, log into your BCBSIL member portal, use the "Find a Drug" tool, and enter "Jardiance" or "empagliflozin." The result will display the tier, any quantity limits, and whether prior authorization applies. You can also call the member services number on the back of your insurance card and ask a representative to look up the drug's formulary status for your specific plan ID.

Prior Authorization and Step Therapy Requirements

BCBSIL frequently requires prior authorization for Jardiance, which means your prescribing physician must submit clinical documentation proving the drug is medically necessary before the pharmacy can fill the prescription. This is standard practice. Most BCBSIL plans also impose step therapy, meaning you must have tried and either failed or shown intolerance to metformin before Jardiance will be approved 2.

The prior authorization process typically involves your doctor submitting a form that includes your current A1C level, a list of previously tried diabetes medications, documentation of metformin intolerance or contraindication (such as an eGFR below 30 mL/min/1.73 m²), and any relevant cardiovascular or renal diagnoses. BCBSIL generally processes prior authorization requests within 72 hours for standard requests and 24 hours for urgent requests.

If your physician documents that you have established cardiovascular disease or heart failure (NYHA class II-IV), approval rates tend to be higher. The EMPA-REG OUTCOME trial (N=7,020) demonstrated that empagliflozin reduced cardiovascular death by 38% compared to placebo in patients with type 2 diabetes and established cardiovascular disease (HR 0.62, 95% CI 0.49-0.77, P<0.001) 3. Insurers recognize this mortality benefit, and cardiovascular comorbidity strengthens the clinical case for approval.

Dr. Silvio Inzucchi, Professor of Medicine at Yale School of Medicine and a principal investigator in the EMPA-REG OUTCOME trial, stated: "The cardiovascular mortality reduction with empagliflozin was unlike anything we had seen with a glucose-lowering agent. This changed the treatment algorithm for patients with type 2 diabetes and heart disease" 3.

What Jardiance Costs on a BCBSIL Plan

Your actual out-of-pocket expense depends on which BCBSIL plan you carry, your deductible status, and whether you use a copay assistance program. On a Tier 3 preferred brand placement with a typical BCBSIL PPO plan, expect a copay of $40 to $75 per month after meeting your deductible. On Tier 4 non-preferred brand placement, monthly copays can range from $75 to $150 or may be calculated as 25% to 40% coinsurance.

Without any insurance, Jardiance carries a retail price of roughly $570 to $620 for 30 tablets. That number drops significantly with coverage. Boehringer Ingelheim offers a manufacturer copay savings card that can bring costs to as low as $10 per month for commercially insured patients, with a maximum annual benefit of $6,000 4. This card cannot be used with Medicare, Medicaid, or other federal healthcare programs.

For Medicare Advantage members on BCBSIL plans, Jardiance falls under Part D prescription coverage. You will typically pay a higher coinsurance in the initial coverage phase (often 25% to 33%) and may enter the coverage gap ("donut hole") sooner because of the drug's brand-name price. Once you reach catastrophic coverage, your share drops to 5% of the drug's cost. The Inflation Reduction Act of 2022 capped total annual out-of-pocket Part D spending at $2,000 beginning in 2025, which provides meaningful relief for patients taking expensive brand-name medications like Jardiance 5.

How to Check Your Specific BCBSIL Plan

Not all BCBSIL plans are identical. The same employer might offer a Blue Choice PPO and a Blue Advantage HMO, each with a different formulary. Here is the fastest way to verify your coverage.

First, visit the BCBSIL member portal at bcbsil.com and log in. Manage to "Pharmacy" or "Prescription Coverage," then search the formulary for empagliflozin or Jardiance. The system will return your plan-specific tier, any prior authorization flag, quantity limits (usually 30 tablets per 30 days), and step therapy requirements. Second, if you cannot access the portal, call BCBSIL member services. Have your member ID and the drug name ready. Ask specifically: "What tier is Jardiance on my formulary, and does it require prior authorization?" Third, your prescribing physician's office can run a real-time benefit check through their electronic health record system, which will return your expected copay before the prescription is even sent to the pharmacy.

A 2023 analysis published in JAMA Internal Medicine found that 29% of patients prescribed an SGLT2 inhibitor faced insurance-related delays, including prior authorization processing and step therapy requirements, with a median delay of 7 days 6. Checking your coverage proactively, before your appointment, can shorten this delay.

What to Do If BCBSIL Denies Jardiance Coverage

A denial is not the final answer. BCBSIL members have the right to appeal, and success rates for well-documented appeals are reasonable. The first step is understanding why the claim was denied. Common reasons include: missing prior authorization, failure to complete step therapy, or the plan classifying Jardiance as non-formulary.

If you receive a denial, ask your prescriber to file a formulary exception request. This requires a letter of medical necessity explaining why Jardiance is clinically appropriate for you and why alternatives (such as metformin, a sulfonylurea, or a different SGLT2 inhibitor like dapagliflozin) are unsuitable. Include supporting lab values (A1C, eGFR, UACR), cardiovascular history, and relevant guideline citations.

The ADA 2024 Standards of Care explicitly state: "For patients with type 2 diabetes and established ASCVD, heart failure, or CKD, an SGLT2 inhibitor with demonstrated benefit is recommended independent of A1C and independent of metformin use" 1. Citing this recommendation directly in the appeal strengthens the case.

BCBSIL offers two levels of internal appeal. If both internal appeals fail, Illinois residents can request an external review through the Illinois Department of Insurance. External reviews are conducted by independent physicians who are not affiliated with BCBSIL, and their decisions are binding on the insurer.

Jardiance vs. Other Covered SGLT2 Inhibitors on BCBSIL

BCBSIL formularies may cover multiple SGLT2 inhibitors, and the tier placement can differ. Farxiga (dapagliflozin) sometimes sits on a preferred tier when Jardiance does not, or vice versa. If your goal is an SGLT2 inhibitor and your plan places Farxiga at a lower copay tier, switching may be a practical option, though the clinical evidence profiles are not identical.

In the EMPA-REG OUTCOME trial, empagliflozin reduced major adverse cardiovascular events (MACE) by 14% (HR 0.86, 95% CI 0.74-0.99, P=0.04) and cardiovascular death by 38% in patients with established cardiovascular disease 3. Dapagliflozin, studied in the DECLARE-TIMI 58 trial (N=17,160), reduced hospitalizations for heart failure by 27% (HR 0.73, 95% CI 0.61-0.88) but did not significantly reduce MACE in the broader population 7. Both drugs carry FDA approval for type 2 diabetes and heart failure, but empagliflozin has the stronger mortality signal in its cardiovascular outcomes trial.

If your physician specifically prescribed Jardiance because of your cardiovascular risk profile, that clinical rationale should be documented in any appeal or formulary exception request. A blanket switch to whichever SGLT2 inhibitor is cheapest ignores differences in evidence that may matter for your health.

Employer-Sponsored vs. Marketplace vs. Medicare Plans

The type of BCBSIL plan you hold affects Jardiance coverage in specific ways. Employer-sponsored plans (also called group plans) often have more generous formularies and lower cost-sharing because the employer subsidizes a portion of the premium and negotiates benefits. Large employer groups in Illinois may place Jardiance on Tier 2 (preferred brand with lower copay) if their pharmacy benefit manager has negotiated a rebate with Boehringer Ingelheim.

Marketplace plans purchased through Get Covered Illinois (the state ACA exchange) must cover all Essential Health Benefits, which include prescription drug coverage. Jardiance will be on the formulary of most Silver and Gold tier plans, though Bronze plans with higher deductibles may require you to pay the full negotiated price until you meet your deductible. A 2022 study in Health Affairs found that ACA Marketplace enrollees paid an average of 46% more out-of-pocket for brand-name diabetes medications compared to employer-sponsored plan members 8.

Medicare Advantage plans through BCBSIL follow Part D formulary rules, which are regulated by the Centers for Medicare & Medicaid Services (CMS). CMS requires that Part D plans cover at least two drugs in each pharmacologic class, so at least one SGLT2 inhibitor must appear on the formulary. BCBSIL Medicare Advantage plans typically cover both Jardiance and Farxiga, though tier placement varies by plan year 9.

Copay Assistance and Patient Support Programs

Several programs exist to reduce your Jardiance costs beyond what BCBSIL covers. The Boehringer Ingelheim Jardiance Savings Card is the most widely used option for commercially insured patients. Eligible patients pay as little as $10 per month, with the card covering up to $6,000 in annual copay costs. The card is not available to patients with government-funded insurance (Medicare, Medicaid, Tricare, VA).

For Medicare patients who face high cost-sharing, the Medicare Extra Help (Low-Income Subsidy) program can reduce Part D costs significantly. Patients with incomes below 150% of the federal poverty level may qualify for subsidies that reduce copays to $4.50 for generic drugs and $11.20 for brand-name drugs in 2025 10.

Boehringer Ingelheim also operates a patient assistance program (PAP) for uninsured or underinsured patients who meet income criteria (generally household income at or below 400% of the federal poverty level). Approved applicants receive Jardiance at no cost. The application requires proof of income, a prescription, and a signed physician statement. Processing typically takes 4 to 6 weeks.

State-level resources exist as well. The Illinois Department on Aging operates a pharmaceutical assistance program for seniors, and community health centers across Illinois may have access to 340B pricing that can reduce Jardiance costs for qualifying patients 11.

Clinical Reasons Your Doctor Prescribed Jardiance Specifically

Your prescriber may have chosen Jardiance over other diabetes medications for reasons beyond blood sugar control. Empagliflozin has FDA approval for reducing cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, as well as for treating heart failure with reduced ejection fraction regardless of diabetes status.

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure by 25% (HR 0.75, 95% CI 0.65-0.86, P<0.001) in patients with heart failure and ejection fraction of 40% or below 12. The EMPA-KIDNEY trial (N=6,609) demonstrated a 28% reduction in kidney disease progression or cardiovascular death (HR 0.72, 95% CI 0.64-0.82, P<0.001) 13. These benefits extend beyond A1C reduction, which is why guidelines now recommend SGLT2 inhibitors based on comorbidities rather than glucose levels alone.

If your BCBSIL plan requires step therapy or favors a different SGLT2 inhibitor, ask your physician whether empagliflozin's specific trial data applies to your clinical situation. That conversation should inform whether you pursue a formulary exception or accept an alternative.